

AUTISM

The Latest Story: Evidence and Safer Care

Audience: RN/APRN | **Contact hrs (proposed):** 1.5 | **Pharmacology hrs:** 0.4

Expected revision: October 5, 2028

Pharmacology hours are included in the total contact hours.

Recognize the person, not a stereotype

A toddler stops using familiar words. A school-age child can recite complex facts but cannot explain that a tooth hurts. A teenager earns good grades while becoming exhausted by the effort of managing conversations. Each presentation calls for careful assessment rather than a quick judgment about what autism is supposed to look like. Autism spectrum disorder (ASD) is a lifelong neurodevelopmental condition with highly variable communication, learning, sensory, and support needs. A diagnosis identifies a pattern; it does not describe the whole person. (Centers for Disease Control and Prevention [CDC], 2025; American Speech-Language-Hearing Association [ASHA], n.d.-b).

The useful clinical question is not simply whether a child has autism. It is what the child can do, what has changed, which barriers interfere with daily life, and what support can begin now. Respectful care recognizes strengths and disability together. It neither promises a cure nor assumes that substantial support needs prevent meaningful learning, participation, or relationships. Five fictional cases illustrate decisions throughout this article.

Purpose, audience, and learning outcomes

This article prepares RNs and APRNs to recognize developmental concerns, interpret assessment findings in context, and coordinate safer, individualized care. The focus is children and adolescents, with attention to transition into adult services. RNs assess, communicate, educate, administer authorized treatments, and escalate concerns. Diagnostic and prescribing decisions require appropriate preparation, authorization, and local privileges. U.S. drug labeling is identified explicitly; it is not a worldwide prescribing standard.

After completing the activity, learners should be able to: distinguish identified prevalence from individual risk; select timely screening and referral actions; differentiate autism from, or recognize its coexistence with, global developmental delay and intellectual disability; design

communication, sensory, and functional supports; identify medication targets and monitor adverse effects; and appraise emerging treatment claims while planning continuity of care.


What the latest prevalence figures mean

The CDC's 2025 surveillance report describes children observed in 2022, not children newly diagnosed in 2025 or 2026. Across 16 Autism and Developmental Disabilities Monitoring (ADDM) Network sites, 32.2 per 1,000 children aged eight years were identified with ASD—approximately one in 31. Site estimates ranged from 9.7 to 53.1 per 1,000. These are selected surveillance communities, not a nationally representative probability sample. The estimate is useful for service planning but should not be treated as a universal rate for every clinic, country, or age group. (Shaw et al., 2025).

Prevalence counts people identified as having a condition in a defined population. Incidence concerns new cases over time. Greater recognition, diagnostic practices, records available to surveillance, and access to services can change identified prevalence. A rising number alone does not reveal which biological or social factors caused the change. Similarly, comparing a registry-based survey with repeated community screening can confuse different case-finding methods with true geographic differences.

The World Health Organization reports a global estimate of about one in 127 people in 2021. That all-age estimate is not directly comparable with the ADDM figure for eight-year-olds in selected U.S. communities. Many lower-resource countries still lack robust prevalence data. Small clinic samples may overrepresent children with more apparent disabilities or families who can travel and pay for assessment. A lower recorded prevalence can therefore coexist with major unmet need. (World Health Organization [WHO], 2025).

One person. Several developmental domains.



A profile informs support. No one domain measures the whole person.

Figure 1. A multidimensional profile guides care. Assess each domain in context; this schematic is not a severity scale or a measured patient profile.

Sources: CDC (2025); AAIDD (n.d.); ASHA (n.d.-a, n.d.-b).

In ADDM, boys were identified more often than girls, and estimates differed across racial and ethnic groups. These findings must not become rules for deciding who deserves evaluation. Population categories do not establish a cause for an individual child. Ask whether referral pathways, interpreter access, clinician expectations, and documentation practices make some children easier to identify than others. (Shaw et al., 2025).

Use denominators when counseling

In the same report, 39.6% of children with ASD who had cognitive information available were classified as having intellectual disability. Cognitive information was available for only 61.4% of the identified eight-year-olds. Quoting 39.6% without that qualification overstates what the data establish. Surveillance classification also differs from a comprehensive individual diagnosis incorporating adaptive functioning. Figure 1 emphasizes why separate domains matter more than a single severity label. (Shaw et al., 2025; American Association on Intellectual and Developmental Disabilities [AAIDD], n.d.).

For a family, translate surveillance into action rather than alarm: developmental concerns are common enough to justify reliable screening systems and accessible services. For a care team, useful local measures include time from concern to referral, completion of diagnostic evaluation, access to communication support, and whether the family actually reached the recommended service. These measures are more actionable than assuming that a national statistic describes local access.

Developmental level changes the presentation

Current diagnostic criteria require persistent difficulties in all three areas of social communication and interaction, together with at least two of four restricted or repetitive behavior categories. These include repetitive movement or speech, insistence on sameness, highly focused interests, and unusual sensory responses. Features arise in the developmental period, affect functioning, and are not better explained by intellectual disability alone. Some become more obvious only when social demands exceed available skills or compensatory strategies. (CDC, 2025).

A child may enjoy affection, share humor, make eye contact, or have friends and still meet ASD criteria. Conversely, avoiding eye contact, flapping hands, or speaking late does not establish ASD. Consider the pattern across settings and development. Social communication includes how a person initiates, responds, shares attention, and coordinates different communication methods—not simply whether the person looks at an examiner.

Intellectual ability is not a single bedside observation

Intellectual disability requires significant limitations in intellectual functioning and adaptive behavior arising during development. Adaptive functioning concerns conceptual, social, and practical everyday skills. An intelligence quotient (IQ) result near a cutoff is not the entire diagnosis. Global developmental delay (GDD) describes significant delay in multiple developmental domains in a young child when a reliable, specific intellectual assessment may not yet be possible. (AAIDD, n.d.; Rodan et al., 2025).

Spoken language and intellectual ability must be assessed separately. A child who cannot answer spoken test questions may have a motor speech difficulty, limited comprehension of the test language, anxiety, hearing loss, or an inaccessible response method. A child with fluent vocabulary may still need substantial support with planning, self-care, flexible problem solving, or understanding another person's meaning. Record what the test measured and what prevented participation before turning a score into a prognosis.

Age-equivalent scores can help explain a particular task result, but they do not convert an older child into a younger person. Use chronological age for dignity, safeguarding, interests, and relationships while adapting task demands to demonstrated abilities. Standardized testing, adaptive history, language assessment, and observation should inform one another. Reassessment matters because access, learning, and the reliability of testing can change over time. (Hyman et al., 2020; Rodan et al., 2025).

Autism and GDD can coexist

Distinguishing ASD from GDD is especially difficult when developmental functioning is very low. An absent skill is informative only if that skill is reasonably expected at the child's developmental level. Lack of elaborate pretend play is less discriminating in a child who has not yet acquired simpler play skills. Assess social interest, reciprocity, communication attempts,

and restricted or repetitive patterns in relation to the entire developmental profile rather than using one missing milestone. (Miller et al., 2019).

In a study of two-year-olds with low developmental functioning, the Autism Diagnostic Observation Schedule (ADOS) sometimes overclassified ASD; the Childhood Autism Rating Scale (CARS) could both overclassify and underclassify it. This finding supports caution about tool interpretation, not a rule that one instrument is always superior. Instrument version, module, age, language, motor abilities, and examiner training all matter. Neither a research subgroup nor a score replaces the diagnostic clinician's synthesis. (Miller et al., 2019).

Case 1 | Delay is real; the diagnosis still needs context

A 26-month-old has delays in motor, language, and problem-solving skills. During testing she does not point or engage in pretend play, but seeks her father's help, shares enjoyment in a familiar song, and responds to simple social games. An elevated observational score prompts concern for ASD. The nurse documents both difficulties and social strengths, requests assessment of hearing, language, cognition, and adaptive functioning, and helps the family begin developmental services. The diagnostic team evaluates whether social communication is below what her broader developmental level would predict. GDD does not exclude ASD, but absent advanced play alone cannot establish it. (Miller et al., 2019; CDC, 2025).

From first concern to a useful assessment

Developmental surveillance is an ongoing conversation at health visits: ask about caregiver concerns, review progress and loss of skills, observe interaction, and incorporate information from other settings. Standardized developmental screening and autism-specific screening serve different purposes. The American Academy of Pediatrics (AAP) recommends autism-specific screening at 18 and 24 months, alongside broader developmental surveillance and screening. Concern at another age still warrants action; the screening calendar is not a reason to wait. (Hyman et al., 2020).

Ask for concrete examples: what words or gestures the child uses to request help, how the child shares interest,

A concern opens parallel pathways—not a queue.




Figure 2. Diagnostic assessment and useful support proceed together. A negative screen does not override regression or a persistent clinical concern. Use the authorized screening instrument separately.
Sources: Hyman et al. (2020); Robins (n.d.).

whether the child responds to sounds and familiar voices, and what happens during changes in routine. Compare current skills with the child's own previous functioning. A report that a child no longer uses previously established communication or motor skills deserves timely medical and developmental assessment. Acute altered awareness, a new focal deficit, or ongoing seizure activity requires an urgent pathway rather than a routine autism referral.

Screening estimates likelihood; it does not diagnose

The Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F), is intended for toddlers aged 16–30 months. Its structured follow-up is an essential part of the process for intermediate scores, not an optional reassurance interview. A score of 0–2 generally needs no follow-up interview, but clinical concern still overrides a negative screen. Scores of 3–7 require the specified follow-up; two or more persisting failed items warrant referral. Scores of 8–20 warrant direct referral without the follow-up interview. (Robins, n.d.).

Use the authorized instrument and scoring instructions in an appropriate language rather than an improvised

questionnaire. The numbers above summarize clinical interpretation; they do not reproduce the instrument. Explain that a positive result can identify children needing developmental services even when a later evaluation does not establish ASD. A negative result does not guarantee that future social demands will not reveal difficulties. Figure 2 shows the parallel tasks that follow a meaningful concern.

Case 2 | Do not let a waiting list become “wait and see”

At 20 months, a child has an M-CHAT-R score of 5. After the authorized follow-up interview, three items remain positive. The caregiver is told that specialist assessment may take several months. The appropriate next step is concurrent diagnostic referral, early-intervention referral, and assessment of hearing and broader development—not repeating the screen at age three before taking action. The nurse documents the result, explains why it is not a diagnosis, identifies a referral contact, and arranges a check that the family connected with services. (Robins, n.d.; Hyman et al., 2020).

Table 1. Questions that prevent diagnostic shortcuts

Finding	Useful next question
Limited speech	What are receptive language, hearing, motor speech, and nonspeaking communication abilities?
No pretend play	Is this task expected at the child's developmental level? What simpler social play is present?
Repetitive movement	Does it occur with a broader ASD pattern, and is it harmful or a useful regulation strategy?
High grades or fluent speech	What effort, sensory burden, adaptive difficulties, or hidden support needs are present?
New loss of function	Is there pain, illness, medication toxicity, seizure activity, or another neurologic condition?

Clinical synthesis from CDC (2025), Hyman et al. (2020), Miller et al. (2019), and ASHA (n.d.-b).

Assemble a profile, not a stack of scores

A comprehensive assessment integrates developmental and medical history, caregiver and educational information, direct observation, language and cognitive assessment, and adaptive functioning. Hearing and vision deserve attention when communication or developmental concerns arise. Physical and neurologic examination can identify additional conditions. ADOS-2, the Autism Diagnostic Interview–Revised, and CARS-2 can contribute structured information, but no single measure is sufficient for every child. Research measures designed for very young infants are not substitutes for a clinical diagnostic process. (CDC, 2025; Hyman et al., 2020).

Electroencephalography (EEG) and brain magnetic resonance imaging (MRI) do not diagnose autism and are not routine screening tests for every autistic child. A seizure history, unusual regression, focal neurologic findings, or other clinical features may justify targeted neurologic investigation. Genetic testing addresses etiology and associated risks; it does not decide whether a child's behavior meets ASD criteria. Families benefit from hearing the purpose of each test before it is ordered. (Hyman et al., 2020; Rodan et al., 2025).

Differential assessment should consider language disorder, hearing differences, GDD or intellectual disability, attention-deficit/hyperactivity disorder (ADHD), anxiety, trauma-related difficulties, and other neurologic or genetic conditions. Several may coexist. A child can be both autistic and anxious, or autistic and hard of hearing. The task is not to choose a single explanation prematurely, but to decide which findings each diagnosis explains and which needs remain unmet.

Girls, camouflaging, and equitable recognition

Some children camouflage difficulties by rehearsing conversations, copying peers, suppressing visible movements, or remaining quiet when confused. The apparent success of these strategies during a brief appointment can obscure distress elsewhere. Girls and verbally fluent children may be missed when referral depends on stereotypes of socially isolated boys with obvious language delay. Camouflaging is not exclusive to girls, and it should not itself be used as a diagnostic test. (ASHA, n.d.-b; Hyman et al., 2020).

Ask about the cost of participation: recovery time after school, avoidance of noisy environments, difficulty sustaining friendships, and whether an apparently ordinary interest is unusually intense or inflexible. Obtain information from more than one setting, but do not require every observer to notice the same difficulties. Differences between reports may reveal environmental demands, access to support, bullying, or compensatory effort rather than an unreliable caregiver.

Case 3 | A reassuring classroom report is not the whole assessment

A 14-year-old with strong grades is referred for escalating anxiety and school avoidance. Her teacher describes polite behavior and a small friendship group. At home, she describes rehearsing every conversation, distress with unexpected changes, and hours of recovery after noisy school days. The APRN assesses anxiety, safety, bullying, developmental history, and possible ASD rather than dismissing the concern because she makes eye

contact. The nurse helps identify quieter waiting arrangements and written communication options. Support for current distress can begin while diagnostic evaluation continues. (ASHA, n.d.-b; Hyman et al., 2020).

Culturally responsive assessment includes trained interpreters, validated translations where available, and questions about expectations in the family's community. Do not mistake limited proficiency in the assessment language for impaired understanding, or demand abandonment of a home language as an autism treatment. Transportation, cost, work schedules, and digital access affect whether referrals succeed. Give families a clear contact point and a practical plan when an appointment is unavailable. (ASHA, n.d.-b; WHO, 2025).

Biology, genetic evaluation, and causal claims

Autism is heterogeneous: different combinations of inherited variation, new genetic variants, developmental processes, and environmental influences can contribute. A single neurotransmitter imbalance or a fixed percentage split between genes and environment does not explain every autistic person. Genetic associations do not imply that outcomes are predetermined, and the absence of an identified genetic explanation does not invalidate a clinical diagnosis. (Rodan et al., 2025; Ozonoff et al., 2024).

The 2024 Baby Siblings Research Consortium study followed 1,605 younger siblings of autistic children and identified ASD in 20.2% by age three. This is a prospective familial-recurrence estimate in a defined research sample, not a personal probability that applies equally to every family. It supports attentive surveillance of younger siblings. Counseling should incorporate the family history, any specific molecular diagnosis, and the limits of available estimates. (Ozonoff et al., 2024).

Genetic testing has moved beyond a rigid older sequence

Offer families an etiologic evaluation appropriate to the presentation and local access. The AAP's 2025 report for GDD and intellectual disability recommends genome sequencing, or exome sequencing with chromosome microarray, as first-tier testing in most circumstances. Phenotype-directed testing remains important when a specific condition is suspected. This

GDD/ID pathway should not be represented as a universal mandatory sequence for every child with isolated ASD. Genetics consultation helps select tests and interpret uncertain findings. (Rodan et al., 2025).

Before testing, discuss possible diagnostic, negative, or uncertain results; potential additional findings; family implications; and consent. A variant of uncertain significance is not a confirmed explanation and should not automatically trigger a targeted treatment. A result can become more informative with parental testing, a better-defined phenotype, or later reinterpretation. Nurses help families understand why follow-up can remain useful even after a nondiagnostic result.

Association is not proof of causation

Investigations of parental age, pregnancy complications, infection, air pollution, and medication exposures must account for confounding, measurement limitations, and selection. An exposure may correlate with the condition because of another shared factor. Family-comparison studies can help address some shared influences, although no observational design eliminates every limitation. Avoid presenting investigated exposures as a list of things parents did wrong. (Ahlqvist et al., 2024; WHO, 2025).

Vaccines do not cause autism. Continuing vaccination protects children from serious preventable infection; attributing autism to vaccination is not supported by the evidence summarized by WHO. Communicate clearly and respectfully, ask what the family heard, and distinguish a temporal sequence from causation. The fact that developmental differences become more apparent near the ages of routine vaccination does not establish a causal connection. (WHO, 2025).

Questions about acetaminophen in pregnancy require similar care. In a large Swedish study, the small association seen in conventional analyses was not present in sibling comparisons. A causal link with autism was not established. The ACOG advisory continues to support clinically appropriate acetaminophen use in pregnancy. Do not tell a parent that taking a recommended analgesic caused the child's autism, and do not advise abrupt cessation of needed treatment. Pregnancy medication decisions belong with the treating maternity team. (Ahlqvist et al., 2024; American College of Obstetricians and Gynecologists [ACOG], 2025).

Some prenatal drug exposures, especially valproate, warrant established reproductive-risk counseling. That

is different from declaring every medication-associated signal causal. The indication for treatment, alternative options, and the danger of uncontrolled maternal illness all matter. Nurses should direct medication questions to the responsible prescriber rather than suggest unsupervised discontinuation. Counseling must separate preventable treatment risks from blame for an existing developmental condition. (WHO, 2025; Hyman et al., 2020).

Mechanism is a starting point for research, not a prescription

Studies of serotonin, dopamine, glutamate, gamma-aminobutyric acid (GABA), synaptic development, immune signaling, and predictive processing generate hypotheses. A blood measurement, animal behavior, or brain-imaging group difference does not automatically become a diagnostic biomarker or prove that changing that pathway will improve everyday functioning. Antipsychotic benefit for severe irritability, for example, does not establish that dopamine dysfunction causes autism. Ask whether the proposed intervention has credible controlled human evidence for the actual target, age group, and outcome. (Hyman et al., 2020; Cook, 2016).

Support communication and meaningful participation

Intervention should begin with goals that matter to the child and family: expressing pain, asking for a break, participating in meals, accessing learning, sleeping better, or staying safe near traffic. A plan is stronger when it names the skill, the environment, the support required, and how improvement will be recognized. Broad promises to normalize behavior are not adequate treatment goals. Autistic people's preferences and assent should inform the plan alongside caregiver knowledge and safety needs. (ASHA, n.d.-b; WHO, 2025).

Developmental, behavioral, educational, and parent-mediated approaches may support specific skills. Applied behavior analysis describes a family of methods rather than one uniform program. Naturalistic developmental behavioral interventions combine developmental targets with learning opportunities during play and daily routines. Choice should reflect age, communication access, child and family priorities, skilled delivery, and ongoing evaluation—not an assumption that every child needs the same schedule or intensity. (Hyman et al., 2020; Sandbank et al., 2023).

The updated Project AIM synthesis found evidence of benefits for some intervention-outcome combinations while highlighting problems with bias, outcome measurement, and reporting of adverse events. Results on a trained task should not be assumed to generalize to school, home, quality of life, or long-term independence. Discuss expected benefit honestly and review whether the actual child is gaining useful skills without unacceptable distress. Neither a branded program nor a large number of therapy hours guarantees a particular outcome. (Sandbank et al., 2023).

Access to communication is a safety intervention

Augmentative and alternative communication (AAC) can supplement speech or provide another route to expression. It may include gestures, pictures, written words, a communication board, or a speech-generating device. There is no prerequisite IQ or speech level that must be achieved before considering AAC. Some people with fluent speech need an alternative method when stressed or unwell. Involve a speech-language pathologist and preserve access across home, school, transport, and health care. (ASHA, n.d.-a).

Do not remove a communication device as a behavioral consequence or keep it out of reach during examination. Ask how the child communicates yes, no, pain, hunger, and the need to stop. Use one clear instruction, allow processing time, and check understanding without repeatedly escalating the verbal demand. A modeled choice can be more accessible than an open-ended question. Confirm that the person—not a helper's physical prompting—is independently authoring the message. (ASHA, n.d.-b, n.d.-a).

Echolalia can serve a communicative or regulatory function. Listen for what a repeated phrase means in its context rather than labeling all repetition meaningless. Likewise, harmless self-regulatory movement need not be eliminated merely because it looks unusual. Intervention priorities should focus on distress, injury, access, and participation. When a behavior is dangerous, teach an accessible alternative response while addressing the trigger rather than relying on punishment or suppression. (ASHA, n.d.-b).


Evaluate a plan in daily life

A useful review distinguishes acquisition from generalization. A child may request a break with one therapist yet be unable to do so in a noisy clinic. Ask whether the same communication support is available, whether staff wait long enough, and whether the child's

Make the encounter accessible before adding demands.

Preview each step.
Agree on a pause.

Reduce glare
and background noise



Keep communication
within reach.

Allow a familiar support person.
Address the child directly.

Illustrative setting: individualized supports, consent, assent, and privacy still apply.

Figure 3. An accessible clinical encounter. Sensory and communication adjustments can reduce preventable distress. The illustrated room and people are schematic, not patient images.

Sources: ASHA (n.d.-a, n.d.-b); Hyman et al. (2020).

request is honored. Lack of carryover can reveal a mismatch in the environment rather than a lack of effort. Record changes in meaningful participation as well as scores.

For limited-resource settings, prioritize feasible supports within existing health and education services. Coaching a caregiver in an agreed communication strategy, providing a low-tech backup board, and coordinating with school may be more achievable than prescribing an unavailable intensive package. Adapt without pretending that a brief encounter is equivalent to a comprehensive intervention. The family should leave knowing the first practical step, who will help, and when progress will be reviewed. (WHO, 2025; ASHA, n.d.-a).

Movement, sensory needs, and co-occurring illness

Motor differences may involve balance, gait, coordination, handwriting, imitation, and the planning of purposeful movement. They deserve assessment because they can affect dressing, feeding, play, communication-device access, and safe mobility. Toe

walking or an unusual gait does not diagnose ASD. New asymmetry, weakness, pain, falls, or loss of a previously established motor skill warrants evaluation for another condition rather than automatic attribution to autism. (Cook, 2016; Hyman et al., 2020).

Research linking movement timing to social perception raises a useful possibility: communication difficulties can reflect a mismatch between people's movement patterns and expectations, not only a deficit within one person. However, motor resonance, mirror-system, and predictive-processing accounts remain explanatory models. They do not justify diagnostic electromyography, a promised cure through imitation training, or an inference about intelligence from movement style. Occupational and physical therapy should target concrete functional difficulties. (Cook, 2016).

Change the encounter before escalating the demand

Figure 3 shows how an examination can be made more accessible. Ask about sensitivity to noise, light, touch, smells, and unexpected changes. Offer a quieter space, preview the sequence, demonstrate equipment, and provide an agreed pause signal. Allow a familiar

support person when appropriate. Address the child directly at an accessible level; do not speak as though a person with limited speech is absent. Obtain consent and seek assent appropriate to the situation. (ASHA, n.d.-b; Hyman et al., 2020).

A sudden increase in distress or self-injury is a clinical signal. Assess pain, dental problems, constipation, reflux, infection, injury, urinary symptoms, sleep loss, seizures, medication changes, and environmental stress. Observe the child's individual pain expression and compare it with baseline. A quiet or atypical response does not exclude serious illness. Record triggers, duration, body language, and what helps; avoid judgmental shorthand such as "noncompliant" when a barrier has not been assessed. (Hyman et al., 2020).

Functional behavioral assessment asks what precedes a behavior, what the behavior achieves or avoids, and what follows it. Medical causes and communication barriers must be investigated alongside those patterns. A child escaping painful toileting needs a medical assessment and an accessible care plan, not simply stronger reinforcement for sitting. If immediate risk is present, use the local emergency and least-restrictive safety pathway while investigating the cause.

Sleep, feeding, and mental health

For sleep difficulty, review schedule, bedtime routines, sleep environment, snoring or breathing pauses, restless sleep, pain, seizures, and medications. Address contributing conditions and establish behavioral sleep strategies before treating insomnia with medication. The American Academy of Neurology (AAN) guideline supports clinician-supervised melatonin when these measures have not been sufficient, using a low starting dose and a reliable pharmaceutical-grade preparation when available. Discuss potential adverse effects and uncertainty about long-term safety. Evidence does not establish weighted blankets as a routine effective treatment for insomnia. (Williams Buckley et al., 2020).

Food selectivity requires more than advice to offer a wider menu. Assess growth trajectory, hydration, nutritional adequacy, oral-motor skill, swallowing, constipation, and sensory factors. A dietitian or feeding team may be needed. Elimination diets should not be presented as an established treatment for autism; a confirmed food allergy, celiac disease, or another medical indication is a separate reason to modify intake. Avoid changes that inadvertently reduce an already

narrow range of tolerated foods. (Hyman et al., 2020; ASHA, n.d.-b).

Anxiety, ADHD, depression, and other mental health conditions can coexist with ASD and deserve their own assessment and treatment. Ask about bullying, distress, self-harm, and suicidal thoughts using an accessible communication method and appropriate privacy. Self-injury may have several functions, and it must not be assumed either to be suicidal or to be harmless. Imminent danger, severe dehydration, altered consciousness, or serious injury needs urgent care, not deferral to a routine behavioral appointment. (Hyman et al., 2020; WHO, 2025).

Medication: define the target and watch for harm

Medication is not a replacement for communication access, education, or an accessible environment. Before prescribing, specify the target: severe irritability with aggression or self-injury, impairing ADHD symptoms, anxiety, epilepsy, or insomnia. Establish a measurable baseline, identify potentially reversible causes, and agree on a review plan. A quieter child is not necessarily a child who is more comfortable or functioning better. Sedation can hide distress and reduce learning or participation. (Hyman et al., 2020).

Risperidone and aripiprazole have U.S. labeling for irritability associated with autistic disorder, not a general indication to treat all core autism features. The current risperidone label describes efficacy studies spanning ages 5–17; the aripiprazole label specifies pediatric patients aged 6–17. Age ranges and dosing refer to particular products and indications. Do not extrapolate an adult schizophrenia schedule, a long-acting injectable regimen, or another country's authorization to a child with ASD. (Janssen Pharmaceuticals, 2026; Otsuka Pharmaceutical, 2025).

Practical prescribing and administration safeguards

Risperidone's pediatric starting dose for this indication is weight-based: 0.25 mg per day below 20 kg and 0.5 mg per day at or above 20 kg. The label permits an increase only after at least four days, followed by a minimum 14-day period at the recommended dose before further adjustments. Subsequent increases are separated by at least two weeks. Individualize to response and tolerability; do not interpret the effective range as a dose every child must reach. Table 2 summarizes the two oral regimens. (Janssen Pharmaceuticals, 2026).

Benefit and treatment burden must be tracked together.

MEANINGFUL BENEFIT

Specify the target first

Fewer injurious episodes
Safer participation
Better access to learning

Use the same measure
before and after treatment.


**Being sleepy is not
the treatment goal.**

POSSIBLE HARM

Alertness and movement
Sedation, akathisia, dystonia

Growth and metabolism
Weight/BMI, appetite, glucose, lipids

Other effects
Pulse, blood pressure, prolactin
symptoms, interactions



Baseline

Early review

Ongoing need

Reassess the plan when benefit is absent, harm develops, or circumstances change.

Figure 4. Medication monitoring has two equally important tracks. Document a meaningful target and adverse effects in parallel. Select a monitoring schedule appropriate to the medicine, patient, and setting.

Sources: Janssen Pharmaceuticals (2026); Otsuka Pharmaceutical (2025).

The aripiprazole regimen starts at 2 mg per day and increases to 5 mg per day, with later changes when needed. Adjustments of up to 5 mg should occur no more frequently than weekly. A new restlessness, pacing, inability to remain still, or complaint of inner discomfort can be akathisia rather than worsening autism or inadequate treatment. Report the temporal relationship to initiation or titration before assuming a higher dose is needed. (Otsuka Pharmaceutical, 2025).

Medication reconciliation includes nonprescription products and drugs prescribed by other teams. Fluoxetine and paroxetine can increase risperidone exposure by inhibiting the drug-metabolizing enzyme CYP2D6; strong CYP2D6 or CYP3A4 inhibitors can require aripiprazole dose adjustment. Enzyme-inducing antiseizure medicines may reduce exposure, and stopping an inducer can change the balance again. The pharmacist and prescriber should review the actual combination rather than relying on a generic interaction warning. (Janssen Pharmaceuticals, 2026; Otsuka Pharmaceutical, 2025).

Monitoring is part of the treatment, not an optional extra

Before and during antipsychotic treatment, track height, weight and body mass index (BMI) trajectory, appetite, blood pressure and pulse, metabolic laboratory results according to the prescribing plan, alertness, sleep, bowel symptoms, and movement findings. Ask about functional benefit in the environments where the target occurs. Risperidone can cause prolactin-related effects, including breast changes or menstrual disturbance. Aripiprazole is not metabolically risk-free. Its labeling also warns about new compulsive behaviors or urges. (Janssen Pharmaceuticals, 2026; Otsuka Pharmaceutical, 2025).

Use a written schedule for early review, follow-up laboratory testing, and reassessment of ongoing need; exact monitoring intervals depend on the medication, risk profile, and local protocol. At each encounter, compare benefit with burden rather than recording only whether a prescription was renewed. Unexpected rapid weight gain, persistent sedation, or new abnormal movements should prompt timely prescriber review. Fever with rigidity, altered mental status, or autonomic instability raises concern for neuroleptic malignant

Table 2. Oral antipsychotics for U.S.-labeled autism-associated irritability

Medication	Starting regimen and titration	Safety boundaries
Risperidone	<20 kg: 0.25 mg/day. ≥20 kg: 0.5 mg/day. After ≥4 days, may increase to 0.5 or 1 mg/day, respectively; maintain ≥14 days. Further increments: 0.25 or 0.5 mg/day at intervals ≥2 weeks.	Effective range: 0.5–3 mg/day. No dosing data below 15 kg. Watch weight/metabolic effects, prolactin effects, sedation, orthostasis, and movement disorders.
Aripiprazole	Ages 6–17: start 2 mg/day; increase to 5 mg/day, then 10 or 15 mg/day if needed. Adjust by ≤5 mg at intervals ≥1 week.	Recommended range: 5–15 mg/day. Watch akathisia, sedation, metabolic effects, orthostasis, and new compulsive urges.

Sources: Janssen Pharmaceuticals (2026), §§1.3 and 2.3; Otsuka Pharmaceutical (2025), §2.4. Educational summary, not an individual prescription. Review the full current label and local protocol.

syndrome and requires emergency assessment. (Janssen Pharmaceuticals, 2026; Otsuka Pharmaceutical, 2025).

Case 4 | “Calmer” is not the only outcome

A 10-year-old taking risperidone for severe, injurious aggression has fewer episodes, but gains 4 kg over eight weeks, falls asleep in class, and develops breast tenderness. The nurse confirms the dose and administration history, records growth and symptoms, and promptly contacts the prescribing clinician. The family is not told to increase the dose for residual episodes or to stop treatment abruptly without a plan. The prescriber reassesses benefit, metabolic and prolactin-related effects, contributing medicines, and whether a lower dose or another strategy is appropriate. Improvement in the target does not cancel the obligation to investigate harm. (Janssen Pharmaceuticals, 2026).

For liquid medication, verify concentration, prescribed milligrams, measured milliliters, and the oral syringe. Risperidone oral solution is 1 mg/mL in the cited product; a 0.25 mg dose therefore equals 0.25 mL. Do not assume every compounded preparation has that concentration. Ask the caregiver to demonstrate measurement and explain the dosing schedule. Written instructions should distinguish a scheduled dose from any separately authorized rescue plan. (Janssen Pharmaceuticals, 2026).

Treat co-occurring conditions, not an assumed universal pathway


Methylphenidate, atomoxetine, and alpha-2 adrenergic agonists may be considered for impairing ADHD

symptoms after a careful assessment. These are symptom- and condition-specific decisions, not established treatments for autism’s entire developmental profile. Monitor attention and participation as well as appetite, sleep, pulse, blood pressure, and emotional changes. Tolerability can differ between children, so a poor response to one treatment does not justify indiscriminate polypharmacy. (Hyman et al., 2020; Scahill et al., 2015).

In an eight-week randomized trial of 62 children with ASD and hyperactivity, extended-release guanfacine improved hyperactivity measures more than placebo. Drowsiness, fatigue, decreased appetite, and reductions in blood pressure or pulse were important safety observations. Guanfacine and clonidine require attention to hypotension, bradycardia, and sedation; discontinuation requires a prescriber-directed taper to avoid rebound effects. Swallow extended-release guanfacine tablets whole; do not crush, chew, or break them, and do not substitute immediate-release and extended-release forms milligram for milligram. (Scahill et al., 2015; Bryant Ranch Prepack, 2026).

Selective serotonin reuptake inhibitors (SSRIs) may be prescribed for an independently assessed anxiety or depressive disorder, but they should not be presented as reliably treating core repetitive behavior in all autistic children. Monitor activation, agitation, sleep changes, and suicidality according to age and indication. Venlafaxine is a serotonin–norepinephrine reuptake inhibitor, not an SSRI. Antiseizure medication is chosen for a diagnosed seizure disorder or another justified indication; it is not routinely prescribed simply because a child has ASD. Product- and age-specific approval

Folate transport: a specific biological problem.



2026 U.S. leucovorin indication: cerebral folate transport deficiency with a confirmed *FOLR1* variant—not autism broadly.

Figure 5. Distinguish a transport disorder from a broad autism claim. CSF = cerebrospinal fluid. This conceptual schematic is not a diagnostic test, dosing guide, or claim that one pathway explains all ASD.

Sources: GlaxoSmithKline (2026); AAP (2026); FDA (2026).

varies; use outside the labeled indication is off-label and requires appropriate counseling. (Hyman et al., 2020).

Clozapine, tricyclic antidepressants, naltrexone, cholinesterase inhibitors, amantadine, and memantine should not appear in routine autism care as interchangeable, established options. Limited trials, uncontrolled observations, or mechanistic arguments do not justify broad prescribing. Exceptional specialist use requires a specific rationale and safety plan. Review medications that no longer provide meaningful benefit and coordinate changes across prescribers. Figure 4 links a measurable target with the parallel obligation to detect treatment burden. (Hyman et al., 2020).

Leucovorin: a narrow approval, not a general autism treatment

In March 2026, the FDA approved an additional indication for oral leucovorin calcium for cerebral folate transport deficiency in adults and children with a confirmed variant in the folate receptor 1 gene (*FOLR1*-CFTD). This is a rare, specific disorder. The approval does not establish leucovorin as a treatment for autism broadly. The exact label is more precise than

headlines referring simply to “folate deficiency” or “autism symptoms.” Figure 5 illustrates the distinction. (U.S. Food and Drug Administration [FDA], 2026; GlaxoSmithKline, 2026).

A child with developmental regression, seizures, abnormal tone or movement, or other neurologic findings may need specialist evaluation for a metabolic or genetic disorder. Cerebral folate deficiency can occur with normal blood folate; a normal serum result does not settle that diagnostic question. Conversely, an isolated commercial antibody result or a common *MTHFR* polymorphism does not establish the labeled *FOLR1* disorder. Testing should follow a neurologic and genetic assessment rather than a universal autism laboratory panel. (American Academy of Pediatrics [AAP], 2026; Rodan et al., 2025).

Small leucovorin studies in autistic children do not establish broad effectiveness or long-term safety. The AAP advises that current evidence is insufficient to support prescribing for autism in the absence of cerebral folate deficiency. A 2024 folinic-acid trial was formally retracted in January 2026; it should not be counted as positive efficacy evidence. Families considering an

off-label intervention need an explanation of uncertainty, alternatives, financial burden, measurable goals, and a plan to stop or revise treatment when benefit is absent or harm emerges. (AAP, 2026; Panda et al., 2026).

Leucovorin is a prescription folate analog, not automatically equivalent to an over-the-counter folic acid supplement. The current label warns about hypersensitivity, certain antiseizure-drug interactions, and enhanced fluorouracil toxicity, and advises avoiding concomitant trimethoprim–sulfamethoxazole. It is not recommended in MTHFS deficiency and is not indicated to treat vitamin B12-deficiency megaloblastic anemia. A specialist should manage treatment for the confirmed disorder; this article does not supply an empiric autism dosing regimen. (GlaxoSmithKline, 2026).

Case 5 | A specific disorder changes the pathway

A five-year-old with an ASD diagnosis develops new gait instability, loss of established skills, and seizures. A relative recommends buying folinic acid because of a news report. The appropriate response is prompt medical and neurologic evaluation, not assuming that regression is simply autism or starting an unsupervised supplement. The team considers genetic and metabolic causes based on the phenotype. If FOLR1-related cerebral folate transport deficiency is confirmed, specialist-directed leucovorin follows the specific indication. Without that diagnosis, a news headline does not establish the same treatment pathway. (AAP, 2026; FDA, 2026).

Continuity, family education, and the next safe decision

Autism care does not end when a diagnostic report is issued. Give the family an understandable summary of strengths, needs, communication methods, associated conditions, and next steps. Use teach-back to check that the plan can be carried out: which service to contact first, what information to bring, which symptoms need urgent attention, and whom to call when a referral fails. A list of telephone numbers without follow-up can leave the most vulnerable families without care.

Safety planning should be individualized. Discuss wandering or elopement, traffic and water exposure, pica, choking, injury, and emergency communication

when relevant. The plan may include supervision arrangements, environmental changes, identification information, and a communication passport describing the person's baseline, pain cues, sensory needs, and effective supports. Do not substitute a diagnosis label for a practical description of how to help this particular child. (Hyman et al., 2020).

As adolescents approach adult care, assess self-management skills, medication knowledge, communication access, education or employment goals, and how appointments will be arranged. Plan transfer of records and identify an adult primary-care clinician and relevant specialists before pediatric services end. Discuss supported decision-making and consent requirements appropriate to the jurisdiction. Do not presume incapacity from an ASD or intellectual-disability diagnosis, and do not assume fluent speech guarantees independent navigation of care. (Hyman et al., 2020; ASHA, n.d.-b).

Caregivers may need respite, emotional support, practical help, and attention to their own health. Ask what is sustainable rather than assigning an idealized schedule that the household cannot maintain. Include siblings and other supports with permission. Internationally, health, education, and community services are organized differently, but continuity still depends on a named contact, shared priorities, and a way to identify a gap before a crisis develops. (WHO, 2025).

Clinical synthesis

The latest story is not a single biomarker, medication, or prevalence headline. It is a more precise approach to a diverse lifelong condition: recognize concerns early, interpret findings against developmental level, and start useful supports while the diagnostic process proceeds. Separate language from cognition, population statistics from individual prediction, and treatment targets from identity. Investigate new distress or regression rather than attributing every change to autism.

A safer plan preserves communication, adapts the environment, treats co-occurring illness, and checks that medication improves a meaningful outcome without excessive burden. Emerging therapies deserve careful evaluation, not automatic dismissal or premature promotion. The strongest next step is one the child and family can use, the team can monitor, and the evidence actually supports.

References

- Ahlqvist, V. H., Sjöqvist, H., Dalman, C., Karlsson, H., Stephansson, O., Johansson, S., Magnusson, C., Gardner, R. M., & Lee, B. K. (2024). Acetaminophen use during pregnancy and children's risk of autism, ADHD, and intellectual disability. *JAMA*, 331(14), 1205–1214.
<https://doi.org/10.1001/jama.2024.3172>
- American Academy of Pediatrics. (2026). *Frequently asked questions for pediatricians and other prescribing pediatric clinicians: Leucovorin use in autism and cerebral folate deficiency*.
<https://www.aap.org/en/patient-care/autism/use-of-leucovorin-in-autistic-pediatric-patients/frequently-asked-questions-faqs-for-pediatricians-and-other-prescribing-pediatric-clinicians/>
- American Association on Intellectual and Developmental Disabilities. (n.d.). *Defining criteria for intellectual disability*.
<https://www.aaidd.org/intellectual-disability/definition>
- American College of Obstetricians and Gynecologists. (2025, September 22). *Acetaminophen use in pregnancy and neurodevelopmental outcomes* [Practice advisory].
<https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2025/09/acetaminophen-use-in-pregnancy-and-neurodevelopmental-outcomes>
- American Speech-Language-Hearing Association. (n.d.-a). *Augmentative and alternative communication (AAC)* [Practice Portal].
<https://www.asha.org/practice-portal/professional-issues/augmentative-and-alternative-communication/>
- American Speech-Language-Hearing Association. (n.d.-b). *Autism and autism spectrum disorder* [Practice Portal].
<https://www.asha.org/practice-portal/clinical-topics/autism/>
- Bryant Ranch Prepack. (2026, July). *Guanfacine extended-release tablets, for oral use* [Prescribing information]. DailyMed.
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6e16cf54-c0d7-47ea-b502-c2146fd87f23&type=display>
- Centers for Disease Control and Prevention. (2025, May 8). *Clinical testing and diagnosis for autism spectrum disorder*.
<https://www.cdc.gov/autism/hcp/diagnosis/index.html>
- Cook, J. (2016). From movement kinematics to social cognition: The case of autism. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 371(1693), 20150372.
<https://doi.org/10.1098/rstb.2015.0372>
- GlaxoSmithKline. (2026, March). *Wellcovorin (leucovorin calcium) tablets, for oral use* [Prescribing information].
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/018342s015lbl.pdf
- Hyman, S. L., Levy, S. E., Myers, S. M., Council on Children with Disabilities, & Section on Developmental and Behavioral Pediatrics. (2020). Identification, evaluation, and management of children with autism spectrum disorder. *Pediatrics*, 145(1), e20193447.
<https://doi.org/10.1542/peds.2019-3447>
- Janssen Pharmaceuticals. (2026, May). *Risperdal (risperidone) tablets, oral solution, and orally disintegrating tablets* [Prescribing information].
<https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RISPERDAL-pi.pdf>
- Miller, L. E., Burke, J. D., Robins, D. L., & Fein, D. A. (2019). Diagnosing autism spectrum disorder in children with low mental age. *Journal of Autism and Developmental Disorders*, 49(3), 1080–1095.
<https://doi.org/10.1007/s10803-018-3810-8>
- Otsuka Pharmaceutical. (2025). *Abilify (aripiprazole) tablets* [Prescribing information].
<https://www.otsuka-us.com/media/static/Abilify-PI.pdf>
- Ozonoff, S., Young, G. S., Bradshaw, J., Charman, T., Chawarska, K., Iverson, J. M., Klaiman, C., Landa, R. J., McDonald, N., Messinger, D., Schmidt, R. J., Wilkinson, C. L., & Zwaigenbaum, L. (2024). Familial recurrence of autism: Updates from the Baby Siblings Research Consortium. *Pediatrics*, 154(2), e2023065297.
<https://doi.org/10.1542/peds.2023-065297>
- Panda, P. K., Sharawat, I. K., Saha, S., Gupta, D., Palayullakandi, A., & Meena, K. (2026). Retraction note: Efficacy of oral folinic acid supplementation in children with autism spectrum disorder: A randomized double-blind, placebo-controlled trial. *European Journal of Pediatrics*, 185, Article 109.
<https://doi.org/10.1007/s00431-026-06769-x>
- Robins, D. L. (n.d.). *Scoring M-CHAT-R/F*.
<https://www.mchatscreen.com/mchat-rf/scoring/>

- Rodan, L. H., Stoler, J., Chen, E., Geleske, T., & Council on Genetics. (2025). Genetic evaluation of the child with intellectual disability or global developmental delay: Clinical report. *Pediatrics*, 156(1), e2025072219.
<https://doi.org/10.1542/peds.2025-072219>
- Sandbank, M., Bottema-Beutel, K., Crowley LaPoint, S., Feldman, J. I., Barrett, D. J., Caldwell, N., Dunham, K., Crank, J., Albarran, S., & Woynaroski, T. (2023). Autism intervention meta-analysis of early childhood studies (Project AIM): Updated systematic review and secondary analysis. *BMJ*, 383, e076733.
<https://doi.org/10.1136/bmj-2023-076733>
- Scahill, L., McCracken, J. T., King, B. H., Rockhill, C., Shah, B., Politte, L., Sanders, R., Minjarez, M., Cowen, J., Mullett, J., Page, C., Ward, D., Deng, Y., Loo, S., Dziura, J., McDougle, C. J., & Research Units on Pediatric Psychopharmacology Autism Network. (2015). Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. *American Journal of Psychiatry*, 172(12), 1197–1206.
<https://doi.org/10.1176/appi.ajp.2015.15010055>
- Shaw, K. A., Williams, S., Patrick, M. E., Valencia-Prado, M., Durkin, M. S., Howerton, E. M., Ladd-Acosta, C. M., Pas, E. T., Bakian, A. V., Bartholomew, P., Nieves-Muñoz, N., Sidwell, K., Alford, A., Bilder, D. A., DiRienzo, M., Fitzgerald, R. T., Furnier, S. M., Hudson, A. E., Pokoski, O. M., ... Maenner, M. J. (2025). Prevalence and early identification of autism spectrum disorder among children aged 4 and 8 years—Autism and Developmental Disabilities Monitoring Network, 16 sites, United States, 2022. *MMWR Surveillance Summaries*, 74(2), 1–22.
<https://doi.org/10.15585/mmwr.ss7402a1>
- U.S. Food and Drug Administration. (2026, March 10). *FDA approves first treatment for patients with cerebral folate transport deficiency*.
<https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-cerebral-folate-transport-deficiency>
- Williams Buckley, A., Hirtz, D., Oskoui, M., Armstrong, M. J., Batra, A., Bridgemohan, C., Coury, D., Dawson, G., Donley, D., Findling, R. L., Gaughan, T., Gloss, D., Gronseth, G., Kessler, R., Merillat, S., Michelson, D., Owens, J., Pringsheim, T., Sikich, L., ... Ashwal, S. (2020). Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*, 94(9), 392–404.
<https://doi.org/10.1212/WNL.00000000000009033>
- World Health Organization. (2025, September 17). *Autism*.
<https://www.who.int/news-room/fact-sheets/detail/autism-spectrum-disorders>